Activation of HIF2α in kidney proximal tubule cells causes abnormal glycogen deposition but not tumorigenesis

Cancer Research

Volumn 73, Issue 9, 2013, Pages 2916-2925

  Fu, Leiping ^a   Wang, Gang ^a   Shevchuk, Maria M ^a   Nanus, David M ^a   Gudas, Lorraine J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD70 ANTIGEN; GAMMA HISTONE H2AX; GLYCOGEN; HISTONE H2AX; HYPOXIA INDUCIBLE FACTOR 2ALPHA; KI 67 ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; GENOME ANALYSIS; GLYCOGEN METABOLISM; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY PROXIMAL TUBULE; MALE; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTOMICS; TRANSGENIC MOUSE;

ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARCINOMA, RENAL CELL; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOGEN; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KIDNEY; KIDNEY NEOPLASMS; KIDNEY TUBULES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION;

EID: 84877732312     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-3983     Document Type: Article

References (46)

1. Maher ER, Kaelin WG Jr. von Hippel-Lindau disease. Medicine (Baltimore) 1997;76:381-91.
2. Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 2005;23:2763-71.
3. Linehan WM, Pinto PA, Srinivasan R, Merino M, Choyke P, Choyke L, et al. Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin Cancer Res 2007;13: 671s-9s.
4. Kaelin WG Jr. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res 2007;13:680s-4s.
5. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010;29:625-34.
6. Gordan JD, Simon MC. Hypoxia-inducible factors: central regulators of the tumor phenotype. Curr Opin Genet Dev 2007;17:71-7.
7. Tian H, McKnight SL, Russell DW. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Gen Dev 1997;11:72-82.
8. Kaelin WG. Von Hippel-Lindau disease. Annu Rev Pathol 2007;2: 145-73.
9. Kondo K, Kim WY, Lechpammer M, Kaelin WG Jr. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 2003;1:E83.
10. Zimmer M, Doucette D, Siddiqui N, Iliopoulos O. Inhibition of hypoxiainducible factor is sufficient for growth suppression of VHL-/- tumors. Mol Cancer Res 2004;2:89-95.
11. Kondo K, Klco J, Nakamura E, Lechpammer M, KaelinWGJr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 2002;1:237-46.
12. Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, Li JL, et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 2005;25:5675-86.
13. Fu L, Wang G, Shevchuk MM, Nanus DM, Gudas LJ. Generation of a mouse model of Von Hippel-Lindau kidney disease leading to renal cancers by expression of a constitutively active mutant of HIF1a. Cancer Res 2011;71:6848-56.
14. Wiesener MS, Munchenhagen PM, Berger I, Morgan NV, Roigas J, Schwiertz A, et al. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res 2001;61:5215-22.
15. Dorevic G, Matusan-Ilijas K, Babarovic E, Hadzisejdic I, Grahovac M, Grahovac B, et al. Hypoxia inducible factor-1alpha correlates with vascular endothelial growth factor A and C indicating worse prognosis in clear cell renal cell carcinoma. J Exp Clin Cancer Res 2009;28:40.
16. Schietke RE, Hackenbeck T, Tran M, Gunther R, Klanke B, Warnecke CL, et al. Renal tubular HIF-2alpha expression requires VHL inactivation and causes fibrosis and cysts. PLoS ONE 2012;7:e31034.
17. Medina Villaamil V, Aparicio Gallego G, Santamarina Cainzos I, Valladares- Ayerbes M, Anton Aparicio LM. Searching for Hif1-alpha interacting proteins in renal cell carcinoma. Clin Transl Oncol 2012;14: 698-708.
18. Biswas S, Charlesworth PJ, Turner GD, Leek R, Thamboo PT, Campo L, et al. CD31 angiogenesis and combined expression of HIF-1alpha and HIF-2alpha are prognostic in primary clear-cell renal cell carcinoma (CC-RCC), but HIFalpha transcriptional products are not: implications for antiangiogenic trials and HIFalpha biomarker studies in primary CC-RCC. Carcinogenesis 2012;33:1717-25.
19. Sivanand S, Pena-Llopis S, Zhao H, Kucejova B, Spence P, Pavia- Jimenez A, et al. A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. Sci Transl Med 2012;4: 137ra75.
20. Jacquemin E, Bulle F, Bernaudin JF, Wellman M, Hugon RN, Guellaen G, et al. Pattern of expression of gamma-glutamyl transpeptidase in rat liver and kidney during development: study by immunochemistry and in situ hybridization. J Pediatr Gastroenterol Nutr 1990;11:89-95.
21. Terzi F, Burtin M, Hekmati M, Federici P, Grimber G, Briand P, et al. Targeted expression of a dominant-negative EGF-R in the kidney reduces tubulo-interstitial lesions after renal injury. J Clin Invest 2000;106:225-34.
22. Li H, Durbin R. Fast and accurate short read alignment with Burrows- Wheeler transform. Bioinformatics 2009;25:1754-60.
23. Dorff KC, Chambwe N, Zeno Z, Shaknovich R, Campagne F. Goby- Web: simplified management and analysis of gene expression and DNA methylation sequencing data; 2012. Available from: http://arxiv. org/abs/1211.6666.
24. Adam PJ, Terrett JA, Steers G, Stockwin L, Loader JA, Fletcher GC, et al. CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding. Br J Cancer 2006;95:298-306.
25. Jilaveanu LB, Sznol J, Aziz SA, Duchen D, Kluger HM, Camp RL. CD70 expression patterns in renal cell carcinoma. Human Pathol 2012;43: 1394-9.
26. McEarchern JA, Smith LM, McDonagh CF, Klussman K, Gordon KA, Morris-Tilden CA, et al. Preclinical characterization of SGN-70, a humanized antibody directed against CD70. Clin Cancer Res 2008;14:7763-72.
27. Wang QJ, Hanada KI, Robbins PF, Li YF, Yang JC. Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma. Cancer Res 2012;72: 6119-29.
28. Gebhard RL, Clayman RV, Prigge WF, Figenshau R, Staley NA, Reesey C, et al. Abnormal cholesterol metabolismin renal clear cell carcinoma. J lipid Res 1987;28:1177-84.
29. Charames GS, Bapat B. Genomic instability and cancer. Curr Mol Med 2003;3:589-96.
30. Loeb KR, Loeb LA. Genetic instability and the mutator phenotype. Studies in ulcerative colitis. Am J Pathol 1999;154:1621-6.
31. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000;182:311-22.
32. Alt JR, Cleveland JL, Hannink M, Diehl JA. Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Gen Dev 2000;14:3102-14.
33. Twardzik DR, Todaro GJ, Marquardt H, Reynolds FH Jr, Stephenson Jr. Transformation induced by Abelson murine leukemia virus involves production of a polypeptide growth factor. Science (New York, NY) 1982;216:894-7.
34. Beroukhim R, Brunet JP, Di Napoli A, Mertz KD, Seeley A, Pires MM, et al. Patterns of gene expression and copy-number alterations in von- Hippel Lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res 2009;69:4674-81.
35. Gumz ML, Zou H, Kreinest PA, Childs AC, Belmonte LS, LeGrand SN, et al. Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clin Cancer Res 2007;13:4740-9.
36. Lenburg ME, Liou LS, Gerry NP, Frampton GM, Cohen HT, Christman MF. Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data. BMC Cancer 2003;3:31.
37. Yusenko MV, Kuiper RP, Boethe T, Ljungberg B, van Kessel AG, Kovacs G. High-resolution DNA copy number and gene expression analyses distinguish chromophobe renal cell carcinomas and renal oncocytomas. BMC Cancer 2009;9:152.
38. Diaz JI, Mora LB, Hakam A. The Mainz classification of renal cell tumors. Cancer Control 1999;6:571-9.
39. Gidekel S, Pizov G, Bergman Y, Pikarsky E. Oct-3/4 is a dose-dependent oncogenic fate determinant. Cancer Cell 2003;4:361-70.
40. Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE, et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 2008;14:435-46.
41. Patel SA, Simon MC. Biology of hypoxia-inducible factor-2alpha in development and disease. Cell Death Differ 2008;15:628-34.
42. Covello KL, Kehler J, Yu H, Gordan JD, Arsham AM, Hu CJ, et al. HIF- 2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth.Gen Dev 2006;20:557-70.
43. Kim WY, Kaelin WG Jr. Molecular pathways in renal cell carcinoma- rationale for targeted treatment. Semin Oncol 2006;33:588-95.
44. Wallace AC, Nairn RC. Renal tubular antigens in kidney tumors. Cancer 1972;29:977-81.
45. Yoshida SO, Imam A, Olson CA, Taylor CR. Proximal renal tubular surface membrane antigens identified in primary and metastatic renal cell carcinomas. Arch Pathol Lab Med 1986;110:825-32.
46. Mandriota SJ, Turner KJ, Davies DR, Murray PG, Morgan NV, Sowter HM, et al. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 2002;1:459-68.